Journals / MN Oftalmoloji / 2017 / Cilt: 24 - Sayı: 1

Meibomian Gland Disease Diagnosis and Treatment

Meibomian Bez Hastalığı Tanı ve Tedavisi

Pages
19–28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the current definition of meibomiangland dysfunction, diagnosis and treatment steps are discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Meibomian gland dysfunction is one of the most important causes of evaporative dry eye disease, and is also one of the mostcommon eye diseases in ophthalmology clinics.
📊
Key Findings & Data:Meibomian gland dysfunction is a chronic and diffuse anomaly characterizedby a quantitative or qualitative secretory change in obstruction and/or glandular secretion in the terminal ducts of the meibomian glands, which may result in tear film layer changes, irritation symptoms, clinically significant inflammation and ocular surface disease.
💡
Conclusion & Impact:In this review, the current definition of meibomiangland dysfunction, diagnosis and treatment steps are discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Meibomian gland dysfunction is one of the most important causes of evaporative dry eye disease, and is also one of the mostcommon eye diseases in ophthalmology clinics. Meibomian gland dysfunction is a chronic and diffuse anomaly characterizedby a quantitative or qualitative secretory change in obstruction and/or glandular secretion in the terminal ducts of the meibomian glands, which may result in tear film layer changes, irritation symptoms, clinically significant inflammation and ocular surface disease. Pathophysiology is multifactorial and disease process is usually progressive. Treatment is long-termand requires good patient compliance; therefore, patients should be informed before treatment begins. It is important to makeassessment tests as early as possible and to provide appropriate treatment. In this review, the current definition of meibomiangland dysfunction, diagnosis and treatment steps are discussed.

Özet

Meibomian bez disfonksiyonu, evaporatif kuru göz hastalığının en önemli nedenlerinden biri olup, aynı zamanda oftalmolojikliniklerinde en sık karşılaşılan göz hastalılarından biridir. Meibomian bez disfonksiyonu, meibomian bezlerin terminal duktuslarında bir obstrüksiyon ve/veya glandüler sekresyonunda kantitatif veya kalitatif bir salgı değişikliği ile karakterize kronikve diffüz bir anomali olup, gözyaşı film tabakası değişiklikleri, irritasyon belirtileri, klinik olarak belirgin enflamasyon ve oküler yüzey hastalığı ile sonuçlanabilir. Meibomian bez disfonksiyonu patogenezi multifaktöryel olup, hastalığın seyri genellikleilerleyici özelliktedir. Tedavi uzun sürelidir ve iyi hasta uyumu gerektirir, bu nedenle tedaviye başlamadan önce hastalar bukonuda bilgilendirilmelidir. Değerlendirme testlerini olabildiğince erken yapmak ve erken tedavi sağlamak önemlidir. Bu derlemede, Meibomian bez disfonksiyonunun güncel tanımı yapılarak, tanı ve tedavi basamakları ele alınmıştır.

🔖

Cite This Article

AKOVA-AYDIN, Y., YEŞİLIRMAK, N. (2017). Meibomian Gland Disease Diagnosis and Treatment. MN Oftalmoloji, Cilt: 24 - Sayı: 1, 19–28. https://ajindex.com/articles/295447

References (14)

  1. Tong L. Chaurasia SS. Mehta JS. Beueman RW. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci 2010; 51:3449-54
  2. Fenga C. Aragona P. Cacciola A. et al. Meibomian gland dysfunction and ocular discomfort in video display terminal workers. Eye 2008;22:91-5
  3. Nichols KK. Foulks GN. Bron AJ. et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011;52: 1922-9
  4. Baudouin C. Messmer EM. Aragona P. et al. Revi si - ting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol 2016;100:300-16
  5. Nelson JD. Shimazaki J. Benitez-del-Castillo JM. et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 2011;52: 1930-7
  6. Arita R. Itoh K. Inoue K. Amano S. Noncontact infra - red meibography to document age-related changes of the meibomian glands in a normal population. Opht - halmology 2008;115:911-5
  7. Tomlinson A. Bron AJ. Korb DR. et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthal - mol Vis Sci 2011;52:2006-49
  8. Knop E. Knop N. Millar T. Obata H. Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci 2011;52:1938-78
  9. Geerling G. Baudouin C. Aragona P. et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocul Surf 2017;15(2):179-92
  10. Schaumberg DA. Nichols JJ. Papas EB. Tong L. Uc - hi no M. Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci 2011; 52:1994-2005
  11. Arita R. Itoh K. Inoue K. Kuchiba A. Yamaguchi T. Amano S. Contact lens wear is associated with decrease of meibomian glands. Ophthalmology 2009; 116:379-84
  12. Sullivan B. Evans J. Cermak J. Krenzer K. Dana M. Sullivan D. Complete androgen insensitivity syndro - me. Arch Ophthalmol 2002;120:1689-99
  13. McCulley JP. Dougherty JM. Deneau DG. Classifi cati - on of chronic blepharitis. Ophthalmology 1982;89: 1173-80
  14. Akova YA. Asena L. Meibomian bez disfonksiyon